Mifepristone Safety: Misinformation and the Congressional Debate

Congressional actions are currently questioning the safety of mifepristone, a medication used in approximately two-thirds of abortions in the United States. These efforts are being driven by misleading data, despite decades of clinical evidence and the support of major medical organizations.

On April 9, 2026, KFF reported that false claims regarding the drug’s safety are fueling legislative and investigative actions in Congress. These developments occur alongside a broader conflict over how health misinformation is moderated and the interpretation of free speech and censorship in policy and law.

Legislative Challenges and Disputed Data

Senator Josh Hawley has cited a report from the faith-centric Ethics and Public Policy Center (EPPC) to support legislation that would revoke the Food and Drug Administration (FDA) approval of mifepristone. The Senator has also called for an investigation into the companies that manufacture and distribute the drug, claiming they ignored safety information.

However, the rate of adverse events cited in the EPPC report is significantly higher than what existing evidence supports. These claims contradict FDA review findings and decades of clinical data.

The safety record of mifepristone is supported by the assessments of major medical organizations, including the American Medical Association (AMA), the World Health Organization (WHO), and the American College of Obstetricians and Gynecologists (ACOG).

Clinical Evidence and Senate Testimony

On January 14, 2026, Dr. Nisha Verma, an ob/gyn practicing in Georgia and Massachusetts and a Fellow with Physicians for Reproductive Health, testified before the United States Senate Committee on Health, Education, Labor, and Pensions.

The fact is: the science on mifepristone’s safety and effectiveness is longstanding and settled. Over the past three decades, mifepristone has been rigorously researched and proven safe and effective in hundreds of high-quality, peer-reviewed studies for both medication abortion and miscarriage management in patients who do not pass the uterine contents on their own.

Dr. Nisha Verma

Dr. Verma noted that mifepristone has been discussed in more than 780 medical reviews and utilized in more than 630 published clinical trials. Of those trials, more than 420 were randomized controlled studies, which are considered the gold standard in research design.

More than 100 of these studies specifically assessed the safety of the drug. Dr. Verma stated that mifepristone has a lower complication rate than many other FDA-approved drugs that are widely available by prescription and over the counter in the United States with fewer restrictions.

Impact on Abortion Access

An October 2025 analysis from the Guttmacher Institute stated that junk science and false narratives regarding mifepristone are being used to further reduce abortion access. The institute affirmed that medication abortion is safe, effective, and widely used both globally and in the United States.

As of 2023, medication abortion accounted for at least 63% of clinician-provided abortions in U.S. States that did not have total bans.

The Guttmacher Institute identified specific ways in which safety data is misrepresented, including:

• Misrepresenting normal signs that a medication abortion is working, such as bleeding or cramping, as serious medical complications.
• Conflating routine or precautionary care-seeking by patients with emergency treatment for serious adverse events.

Political and Regulatory Context

The Guttmacher Institute noted that the arrival of the second Trump administration has placed anti-abortion officials in key leadership roles within federal agencies. This includes the Department of Justice and the FDA, both of which could be prominent in attempts to restrict access to mifepristone.

These legal and policy challenges are compounded by disputes over the moderation of health misinformation. Recent developments, including a federal lawsuit settlement and a Supreme Court ruling, reflect competing interpretations of what constitutes free speech versus censorship in the context of public health information.